XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
A phase 1/2 trial of XNW27011 in ovarian cancer and colorectal cancer, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.
Overview
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. is a phase 1/2 interventional study registered as NCT06792435 by Astellas Pharma Global Development, Inc., with 240 participants planned, started 2023-07-27 and due to reach its primary completion in 2026-12-30. Interventions recorded: XNW27011, XNW27011. Conditions listed: Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic. No results are recorded here; the registry entry is the source.
Setting
A Phase I/Ⅱ, First-in-Human Study of XNW27011 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Phase
Phase 1/2
Sponsor
Astellas Pharma Global Development, Inc.
Registry
Enrolled
240